LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Next-Generation Systems Introduced for Clinical Laboratories

By LabMedica International staff writers
Posted on 17 Aug 2016
A harmonized family of next-generation systems across immunoassay, clinical chemistry, point of care, hematology, blood and plasma screening and molecular diagnostics has been unveiled.

Many institutions and laboratories use multiple diagnostic platforms, often within a larger health care network and as they serve more patients and try to improve service levels with fewer qualified technicians, institutions are looking for new technologies that can help maximize testing efficiencies and help better manage resources.

The Alinity systems (Abbott Diagnostics, Abbott Park, IL, USA) will have the ability to work together, providing greater capacity and simplifying the user experience. Several of the platforms will be designed to run more tests in less space, generate test results faster and minimize human errors. By offering a comprehensive solution that addresses the challenges of using multiple diagnostics platforms, while continuing to provide quality results that positively impact patient care, Alinity could potentially change the industry's testing paradigm.

Abbott expects Alinity launches to begin later this year and continue into 2017. The systems are supported by Abbott's AlinIQ, the first-of-its-kind, combined professional services and informatics solution that assists laboratories in achieving greater operational productivity with their existing resources. AlinIQ launched worldwide in April 2016. To develop each next-generation platform, Abbott's scientific and development teams engaged with thousands of clinicians, scientists, laboratory technicians and health care executives. The goal was to better understand their experiences and learn what is needed to address the challenges they face, whether in the core laboratory, at the point of care or in molecular diagnostics.

Dennis Gilbert, Ph.D., vice president at Abbott Diagnostics Products, said, “Abbott's Alinity systems are being built from the ground up based on customer insights, using the latest technologies suitable for testing today and in the future. Whether it's an easy-to-use software interface, running more tests faster or the ability to run any test at any time, our Alinity platforms are designed to include these features and more without any compromise in performance or quality.” The Alinity System was unveiled during the 68th AACC Annual Scientific Meeting & Clinical Lab Expo held July 31 to August 4, 2016, in Philadelphia, PA, USA.

Related Links:
Abbott Diagnostics
AACC Annual Scientific Meeting & Clinical Lab Expo
Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Homocysteine Quality Control
Liquichek Homocysteine Control
Rapid Molecular Testing Device
FlashDetect Flash10

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more